AU2019395266A1 - IL-15 compositions and methods of use thereof - Google Patents

IL-15 compositions and methods of use thereof Download PDF

Info

Publication number
AU2019395266A1
AU2019395266A1 AU2019395266A AU2019395266A AU2019395266A1 AU 2019395266 A1 AU2019395266 A1 AU 2019395266A1 AU 2019395266 A AU2019395266 A AU 2019395266A AU 2019395266 A AU2019395266 A AU 2019395266A AU 2019395266 A1 AU2019395266 A1 AU 2019395266A1
Authority
AU
Australia
Prior art keywords
activatable proprotein
polypeptide
proprotein
activatable
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019395266A
Other languages
English (en)
Inventor
Zijuan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proviva Therapeutics Hong Kong Ltd
Original Assignee
Proviva Therapeutics Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proviva Therapeutics Hong Kong Ltd filed Critical Proviva Therapeutics Hong Kong Ltd
Publication of AU2019395266A1 publication Critical patent/AU2019395266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019395266A 2018-12-14 2019-12-13 IL-15 compositions and methods of use thereof Abandoned AU2019395266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779793P 2018-12-14 2018-12-14
US62/779,793 2018-12-14
PCT/US2019/066287 WO2020123980A1 (en) 2018-12-14 2019-12-13 Il-15 compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019395266A1 true AU2019395266A1 (en) 2021-06-17

Family

ID=71075819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019395266A Abandoned AU2019395266A1 (en) 2018-12-14 2019-12-13 IL-15 compositions and methods of use thereof

Country Status (8)

Country Link
US (1) US20230045048A1 (https=)
EP (1) EP3893917A4 (https=)
JP (2) JP7557465B2 (https=)
KR (1) KR102911817B1 (https=)
CN (1) CN114746105A (https=)
AU (1) AU2019395266A1 (https=)
CA (1) CA3121813A1 (https=)
WO (1) WO2020123980A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
US20240228585A1 (en) * 2021-05-03 2024-07-11 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis
US20240182537A1 (en) * 2022-08-31 2024-06-06 Proviva Therapeutics (Hong Kong) Limited Il-15 procytokine antibody fusion proteins
WO2024054425A1 (en) * 2022-09-08 2024-03-14 Cugene Inc. Novel pd1-targeted il-15 immunocytokine and vitokine fusions
WO2024216170A2 (en) * 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2025085744A1 (en) * 2023-10-18 2025-04-24 Memorial Sloan-Kettering Cancer Center Fusion polypeptides and uses thereof
WO2025180355A1 (zh) * 2024-02-27 2025-09-04 江苏奥赛康生物医药有限公司 Il-15前药与免疫检查点抑制剂的组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
PT1527100E (pt) * 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) * 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2016004383A1 (en) * 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
CN107709356A (zh) 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
JP2019519516A (ja) * 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド がんの治療のためのｍＲＮＡ併用療法
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
EP3568474A1 (en) * 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems

Also Published As

Publication number Publication date
JP7557465B2 (ja) 2024-09-27
JP2024175026A (ja) 2024-12-17
CA3121813A1 (en) 2020-06-18
EP3893917A1 (en) 2021-10-20
KR102911817B1 (ko) 2026-01-14
EP3893917A4 (en) 2023-01-11
CN114746105A (zh) 2022-07-12
US20230045048A1 (en) 2023-02-09
WO2020123980A1 (en) 2020-06-18
JP2022513888A (ja) 2022-02-09
KR20210104060A (ko) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7557465B2 (ja) Ｉｌ－１５組成物およびその使用方法
JP7631420B2 (ja) ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法
US20240254184A1 (en) Il-15 fusion proteins and methods of making and using the same
HK40106026A (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
HK40098241A (zh) Il-15融合蛋白以及制备和使用其的方法
KR20260061438A (ko) 인간 뉴레귤린-1(nrg-1) 재조합 융합 단백질 조성물 및 이의 사용 방법
EA052095B1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
HK40044003B (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
HK40044003A (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application